1079TiP A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies
Sen S, Spira A, Sommerhalder D, Meric-Bernstam F, Subbiah V, Berlin J, Parikh A, Cecchini M, Sanborn R, Chablani P, Peoples G, Schürpf T, Dillon L, Clifton G, Eder J, Tolcher A. 1079TiP A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies. Annals Of Oncology 2023, 34: s649-s650. DOI: 10.1016/j.annonc.2023.09.2976.Peer-Reviewed Original Research